A fight over how long to protect certain high-end drugs from lower-cost imitators has emerged as the leading obstacle to negotiations aimed at completing the Trans-Pacific Partnership trade agreement.
WSJ.com US News, Wall Street Journal
Thu, 10/01/2015 - 2:52am
A fight over how long to protect certain high-end drugs from lower-cost imitators has emerged as the leading obstacle to negotiations aimed at completing the Trans-Pacific Partnership trade agreement.